Enliven Therapeutics, Inc. Balance Sheet
ELVN / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Enliven Therapeutics, Inc. had $326M in total assets and $310M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $124.1M | $100.1M | $75.5M | $48.3M | $47.7M | $4.9M |
| Current Assets | $318.1M | $266.2M | $77.8M | $92.7M | $90.4M | $30.6M |
| PP&E (Net) | $458.0K | $742.0K | $890.0K | $250.0K | $349.0K | $442.0K |
| Total Assets | $325.8M | $271.9M | $83.3M | $93.6M | $90.8M | $33.3M |
| Current Liabilities | $15.9M | $25.9M | $9.7M | $7.2M | $6.2M | $4.2M |
| Shareholders' Equity | $309.8M | $245.9M | -$76.8M | -$42.9M | $84.4M | -$48.8M |